Effects of tofacitinib monotherapy on patient-reported outcomes in a randomized phase 3 study of patients with active rheumatoid arthritis and inadequate responses to DMARDs

INTRODUCTION: Tofacitinib is an oral Janus kinase inhibitor for the treatment of rheumatoid arthritis. METHOD: In this 6-month, phase 3, randomized, placebo-controlled trial, 611 patients with inadequate response to disease-modifying anti-rheumatic drugs (DMARD-IR) were randomized 4:4:1:1 to receive...

Celý popis

Uloženo v:
Podrobná bibliografie
Vydáno v:Arthritis Res Ther
Hlavní autoři: Strand, Vibeke, Kremer, Joel, Wallenstein, Gene, Kanik, Keith S., Connell, Carol, Gruben, David, Zwillich, Samuel H., Fleischmann, Roy
Médium: Artigo
Jazyk:Inglês
Vydáno: BioMed Central 2015
Témata:
Research Article
On-line přístup:https://ncbi.nlm.nih.gov/pmc/articles/PMC4632359/
https://ncbi.nlm.nih.gov/pubmed/26530039
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s13075-015-0825-9
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!

Podobné jednotky